Reports

Ideas That Generate Results

Immuno-Oncology Market, By Type [mAb (Naked, Conjugate), Cancer Vaccines, Immune Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4]), By Application (Lung, Melanoma, Leukemia, Lymphoma) - Global Forecast to 2022

Immuno-Oncology Market, By Type [mAb (Naked, Conjugate), Cancer Vaccines, Immune Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4]), By Application (Lung, Melanoma, Leukemia, Lymphoma) - Global Forecast to 2022

Format :  Adobe Reader (PDF) Upto 24 hour delivery
Publish Date : Jan, 2020| No. of Pages : 230

Share |
 
Please make your selection :
Electronic Access - Single User License
US$ 3000.00
CD-ROM Mail Delivery
US$ 3500.00
Hard Copy Mail Delivery
US$ 3500.00
Electronic Access - Multi-User License
US$ 6000.00
List of Figures:

Figure 4-1: Global - Cancer Incidences (Million), 2015, 2020, 2025 & 2030
Figure 4-2: Global - Cancer Mortality (Million), 2015, 2020, 2025 & 2030
Figure 4-3: Global - Population above 60 Years (Billion), 2015 & 2050
Figure 4-4: Expected Combination Regimen Launches in Oncology
Figure 5-1: Global - Immuno-Oncology Market (Billion US$), 2016-2022
Figure 6-1: Global - Share of Immuno-Oncology Market by Product (%), 2016
Figure 6-2: Global - Share of Immuno-Oncology Market by Product (%), 2022
Figure 6-3: Global - Monoclonal Antibodies Market (Billion US$), 2016-2022
Figure 6-4: Global - Rituxan Market (Billion US$), 2012-2016
Figure 6-5: Global - Avastin Market (Billion US$), 2012-2016
Figure 6-6: Global - Herceptin Market (Billion US$), 2012-2016
Figure 6-7: Global - ADCETRIS Market (Million US$), 2012-2016
Figure 6-8: Global - Kadcyla Market (Million US$), 2013-2016
Figure 6-9: Global - Blincyto Market (Million US$), 2014-2016
Figure 6-10: Global - Other Monoclonal Antibodies Market (Billion US$), 2016-2022
Figure 6-11: Global - Therapeutic Cancer Vaccines Market (Billion US$), 2016-2022
Figure 6-12: Global - Provenge Market (Million US$), 2012-2016
Figure 6-13: Global - Immune Checkpoint Inhibitors Market (Billion US$), 2016-2022
Figure 6-14: Global - Yervoy Market (Million US$), 2012-2016
Figure 6-15: Global - Opdivo Market (Million US$), 2014-2016
Figure 6-16: Global - Keytruda Market (Million US$), 2014-2016
Figure 6-17: Global - Others Market (Billion US$), 2016-2022
Figure 7-1: Global - Share of Immuno-Oncology Market by Application (%), 2016
Figure 7-2: Global - Share of Immuno-Oncology Market by Application (%), 2022
Figure 7-3: Global - Head & Neck Cancer Market (Billion US$), 2016-2022
Figure 7-4: Head & Neck Cancer - Immunotherapy Pipeline Analysis by Product (%), 2016
Figure 7-5: Head & Neck Cancer - Immunotherapy Pipeline Analysis by Phase (%), 2016
Figure 7-6: Global - Lung Cancer Market (Billion US$), 2016-2022
Figure 7-7: Lung Cancer - Immunotherapy Pipeline Analysis by Product (%), 2016
Figure 7-8: Lung Cancer - Immunotherapy Pipeline Analysis by Phase (%), 2016
Figure 7-9: Global - Melanoma Market (Billion US$), 2016-2022
Figure 7-10: Melanoma - Immunotherapy Pipeline Analysis by Product (%), 2016
Figure 7-11: Melanoma - Immunotherapy Pipeline Analysis by Phase (%), 2016
Figure 7-12: Global - Lymphoma Market (Billion US$), 2016-2022
Figure 7-13: Lymphoma - Immunotherapy Pipeline Analysis by Product (%), 2016
Figure 7-14: Lymphoma - Immunotherapy Pipeline Analysis by Phase (%), 2016
Figure 7-15: Global - Leukemia Market (Billion US$), 2016-2022
Figure 7-16: Leukemia - Immunotherapy Pipeline Analysis by Product (%), 2016
Figure 7-17: Leukemia - Immunotherapy Pipeline Analysis by Phase (%), 2016
Figure 7-18: Global - Other Cancer Market (Billion US$), 2016-2022
Figure 7-19: Other Cancer - Immunotherapy Pipeline Analysis by Product (%), 2016
Figure 7-20: Other Cancer - Immunotherapy Pipeline Analysis by Phase (%), 2016
Figure 8-1: Global - Share of Immuno-Oncology Market by Geographic Regions (%), 2016
Figure 8-2: Global - Share of Immuno-Oncology Market by Geographic Regions (%), 2022
Figure 8-3: North America - Immuno-Oncology Market (Billion US$), 2016-2022
Figure 8-4: Europe - Immuno-Oncology Market (Billion US$), 2016-2022
Figure 8-5: Asia-Pacific - Immuno-Oncology Market (Billion US$), 2016-2022
Figure 9-1: Immuno-Oncology Funding by Product Type (Billion, US$), 2015-2016
Figure 9-2: Major Investors in Immuno-Oncology Market (2015-2016)
Figure 9-3: Bristol-Myers Squibb and Merck & Co. - Strategic Collaborations
Figure 11-1: Global - Immuno-Oncology Pipeline Analysis by Product Type (%), 2016
Figure 11-2: Global - Immuno-Oncology Pipeline Analysis by Phase (%), 2016
Figure 12-1: Global - Share of Key Players in Immuno-Oncology Market (%), 2015
Figure 13-1: F. Hoffmann-La Roche AG - Sales by Business Segments (%), 2016
Figure 13-2: F. Hoffmann-La Roche AG - Pharmaceuticals Division Sales by Segments (%), 2016
Figure 13-3: F. Hoffmann-La Roche AG - Pharmaceuticals Division Sales by Geography (%), 2016
Figure 13-4: Celgene Corporation - Sales by Products (%), 2016
Figure 13-5: Bristol Myers Squibb - Revenue by Business Segments (%), 2016
Figure 13-6: Bristol Myers Squibb - Revenue by Geography (%), 2016
Figure 13-7: Merck & Co., Inc. - Revenue by Business Segments (%), 2016
Figure 13-8: Merck & Co., Inc. - Pharmaceutical Division Revenue by Segments (%), 2016
Figure 13-9: Merck & Co., Inc. - Revenue by Geography (%), 2016
Figure 13-10: Novartis - Sales by Business Segments (%), 2016
Figure 13-11: Novartis - Innovative Medicines Division Sales by Segments (%), 2016
Figure 13-12: Novartis - Pharmaceuticals Division Sales by Segments (%), 2016
Figure 13-13: Novartis - Sales by Geography (%), 2016
Figure 13-14: AstraZeneca Plc - Revenue by Business Segments (%), 2016
Figure 13-15: AstraZeneca Plc - Revenue by Geography (%), 2016
Figure 13-16: Pfizer Inc - Revenue by Business Segments (%), 2016
Figure 13-17: Pfizer Inc - Revenue by Geography (%), 2016
Figure 13-18: Eli Lilly and Company - Revenue by Business Segments (%), 2016
Figure 13-19: Eli Lilly and Company - Human Pharmaceutical Division Revenue by Business Segments (%), 2016
Figure 13-20: Eli Lilly and Company - Revenue by Geography (%), 2016
Figure 13-21: Johnson & Johnson - Sales by Business Segments (%), 2016
Figure 13-22: Johnson & Johnson - Sales by Pharmaceutical Segments (%), 2016
Figure 13-23: Johnson & Johnson - Sales by Geography (%), 2016
Figure 13-24: Amgen Inc. - Sales by Product (%), 2016
Figure 13-25: Amgen Inc. - Sales by Geography (%), 2016

List of Tables:

Table 4-1: Immuno-Oncology - Late Stage Research Pipeline
Table 4-2: US & Europe - Major Drug Patent Expiry in Immuno-Oncology Market
Table 6-1: Ongoing Trials for Rituxan
Table 6-2: Ongoing Trials for Avastin
Table 6-3: Ongoing Trials for Herceptin
Table 6-4: Ongoing Trials for ADCETRIS
Table 6-5: Ongoing Trials for Kadcyla
Table 6-6: Ongoing Trials for Blincyto
Table 6-7: Ongoing Trials for Other Monoclonal Antibodies
Table 6-8: Ongoing Trials for Provenge
Table 6-9: Ongoing Trials for Yervoy
Table 6-10: Ongoing Trials for Opdivo
Table 6-11: Ongoing Trials for Keytruda
Table 6-12: Ongoing Trials for Other Immuno-Oncology Products
Table 7-1: Global - Oncology Incidence by Geography (‘000), 2015 & 2020
Table 9-1: Immuno-Oncology Companies that Received Venture Capital Investments
Table 9-2: Selected Immuno-Oncology and/or Targeted Therapy Combinations
Table 10-1: Strategic Collaborations in the Immuno-Oncology Industry
Table 11-1: Active Immuno-Oncology Programs
Table 11-2: Global – Immuno-Oncology Product Pipeline
Table 13-1: F. Hoffmann-La Roche AG - Key Financials (Billion US$), 2014-2016
Table 13-2: F. Hoffmann-La Roche AG - Commercialized Immuno-Oncology Products
Table 13-3: F. Hoffmann-La Roche AG - Product Pipeline
Table 13-4: Celgene Corporation - Key Financials (Million US$), 2014-2016
Table 13-5: Celgene Corporation - Commercialized Immuno-Oncology Products
Table 13-6: Celgene Corporation - Product Pipeline
Table 13-7: Bristol Myers Squibb - Key Financials (Million US$), 2014-2016
Table 13-8: Bristol Myers Squibb - Commercialized Immuno-Oncology Products
Table 13-9: Bristol Myers Squibb - Product Pipeline
Table 13-10: Merck & Co., Inc. - Key Financials (Million US$), 2014-2016
Table 13-11: Merck & Co., Inc. - Commercialized Immuno-Oncology Products
Table 13-12: Merck & Co., Inc. - Product Pipeline
Table 13-13: Novartis - Key Financials (Billion US$), 2014-2016
Table 13-14: Novartis - Commercialized Immuno-Oncology Products
Table 13-15: Novartis - Product Pipeline
Table 13-16: AstraZeneca Plc - Key Financials (Million US$), 2014-2016
Table 13-17: AstraZeneca Plc - Commercialized Immuno-Oncology Products
Table 13-18: AstraZeneca Plc - Product Pipeline
Table 13-19: Pfizer Inc - Key Financials (Billion US$), 2014-2016
Table 13-20: Pfizer Inc - Commercialized Immuno-Oncology Products
Table 13-21: Pfizer Inc - Product Pipeline
Table 13-22: Eli Lilly and Company - Key Financials (Million US$), 2014-2016
Table 13-23: Eli Lilly and Company - Commercialized Immuno-Oncology Products
Table 13-24: Eli Lilly and Company - Product Pipeline
Table 13-25: Johnson & Johnson - Key Financials (Billion US$), 2014-2016
Table 13-26: Johnson & Johnson - Commercialized Immuno-Oncology Products
Table 13-27: Johnson & Johnson - Product Pipeline
Table 13-28: Amgen Inc. - Key Financials (Billion US$), 2014-2016
Table 13-29: Amgen Inc. - Commercialized Immuno-Oncology Products
Table 13-30: Amgen Inc. - Product Pipeline

Not able to find data you are looking for? Ask our Research Analyst.

media citation

get in touch

Please fill-in the information below.